Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Bicalutamide in AR+ Triple-Negative Breast Cancer
NCT06365788Phase 2Recruiting
- Sponsor
- UZ Leuven
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib and bicalutamide in triple-negative breast cancer (TNBC), sponsored by UZ Leuven. Primary endpoint: Disease Control Rate at 16 weeks. Started Apr 2024; status: recruiting.
02
Drugs
abemaciclibbicalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06365788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365788.